|
|
Vaccine Detail
|
Total Tumor RNA-loaded Dendritic Cell Vaccine |
| Vaccine Information |
- Vaccine Name: Total Tumor RNA-loaded Dendritic Cell Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: whole cell cancer vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: tumor-associated antigens (TAAs) (NCIT_C116913)
- Immunization Route: Intradermal injection (i.d.)
- Description: This is a cancer vaccine containing autologous dendritic cells (DCs) that are loaded with total tumor RNA (TTRNA) from a specific tumor, with potential immunostimulatory and antineoplastic activities. The vaccine may elicit a highly specific cytotoxic T-cell (CTL) response against the tumor-associated antigens (TAAs) encoded by the TTRNA. (NCIT_C116913) The vaccine can be given in combination with Temozolomide (TMZ) and Autologous Hematopoietic Stem Cells (HSC). (NCT03396575)
|
| Host Response |
|
|
| References |
NCIT_C116913: Total Tumor RNA-loaded Dendritic Cell Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C116913]
NCT03396575: Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I) (BRAVO) [https://clinicaltrials.gov/study/NCT03396575]
|
|
